Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ. Lefkovits J, et al. Among authors: topol ej. Am J Cardiol. 1996 May 15;77(12):1045-51. doi: 10.1016/s0002-9149(96)00128-2. Am J Cardiol. 1996. PMID: 8644655 Clinical Trial.
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ; EPIC Investigators; EPILOG investigators; EPISTENT investigators. Kereiakes DJ, et al. Among authors: topol ej. Am J Cardiol. 2002 Sep 15;90(6):628-30. doi: 10.1016/s0002-9149(02)02568-7. Am J Cardiol. 2002. PMID: 12231090 Clinical Trial. No abstract available.
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ; GUSTO V Trial. Gurm HS, et al. Among authors: topol ej. J Am Coll Cardiol. 2004 Feb 18;43(4):542-8. doi: 10.1016/j.jacc.2003.09.038. J Am Coll Cardiol. 2004. PMID: 14975461 Free article. Clinical Trial.
Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Stack RS, Candela RJ, O'Neill WW, Martin LH, Califf RM. Kereiakes DJ, et al. Among authors: topol ej. J Am Coll Cardiol. 1988 May;11(5):899-907. doi: 10.1016/s0735-1097(98)90043-2. J Am Coll Cardiol. 1988. PMID: 2965716 Free article.
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Lincoff AM, Topol EJ, Califf RM, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Ellis SG. Lincoff AM, et al. Among authors: topol ej. Am J Cardiol. 1995 May 1;75(14):871-6. doi: 10.1016/s0002-9149(99)80678-x. Am J Cardiol. 1995. PMID: 7732992 Clinical Trial.
1,206 results